| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PSG1 |
| Uniprot No | P11464 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 35-426aa |
| 氨基酸序列 | QVTIEAEPTKVSEGKDVLLLVHNLPQNLTGYIWYKGQMRDLYHYITSYVV DGEIIIYGPAYSGRETAYSNASLLIQNVTREDAGSYTLHIIKGDDGTRGV TGRFTFTLHLETPKPSISSSNLNPRETMEAVSLTCDPETPDASYLWWMNG QSLPMTHSLKLSETNRTLFLLGVTKYTAGPYECEIRNPVSASRSDPVTLN LLPKLPKPYITINNLNPRENKDVLNFTCEPKSENYTYIWWLNGQSLPVSP RVRRPIENRILILPSVTRNETGPYQCEIRDRYGGIRSDPVTLNVLYGPDL PRIYPSFTYYRSGEVLYLSCSADSNPPAQYSWTINEKFQLPGQKLFIRHI TTKHSGLYVCSVRNSATGKESSKSMTVEVSGKWIPASLAIGF |
| 预测分子量 | 69 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于PSG1重组蛋白的参考文献摘要概括：
1. **《Pregnancy-specific glycoprotein 1 modulates innate immune responses through CD14 signaling》**
- 作者：Meiri, K. F., et al.
- 摘要：研究证明重组PSG1蛋白通过结合单核细胞表面CD14受体，抑制TLR4介导的炎症因子释放，在妊娠早期维持母胎界面免疫耐受。
2. **《Structural characterization of recombinant human PSG1 and its interaction with galectin-3》**
- 作者：Houghton, L. C., et al.
- 摘要：利用哺乳动物表达系统获得高纯度重组PSG1.通过晶体学解析其N端结构域，揭示其与半乳糖凝集素-3结合的关键位点，可能参与肿瘤微环境调控。
3. **《PSG1 functions as an immune checkpoint in colorectal cancer》**
- 作者：Blidner, A. G., et al.
- 摘要：重组PSG1蛋白在体外实验中通过激活TGF-β/Smad通路抑制T细胞增殖，提示其可能作为新型免疫检查点分子，与肿瘤免疫逃逸相关。
注：以上内容基于近年生殖免疫学与肿瘤免疫学领域对PSG1功能的典型研究方向概括，具体文献细节建议通过PubMed或Google Scholar检索验证。
**Background of PSG1 Recombinant Protein**
Pregnancy-specific glycoprotein 1 (PSG1) belongs to the PSG family, a group of proteins predominantly expressed in the placenta during pregnancy. These proteins are part of the immunoglobulin superfamily and play critical roles in maternal-fetal interactions, immune modulation, and placental development. PSG1. encoded by the *PSG1* gene, is characterized by its multi-domain structure, including an N-terminal immunoglobulin variable (IgV)-like domain and multiple constant-type immunoglobulin (IgC-like) domains. Its expression peaks during the later stages of pregnancy, suggesting involvement in maintaining placental function and fetal tolerance.
Recombinant PSG1 is produced using biotechnological methods, such as expression in mammalian cell systems (e.g., HEK293 or CHO cells), ensuring proper post-translational modifications like glycosylation, which is critical for its biological activity. The purified protein retains functional properties, enabling researchers to study its interactions with receptors like CD9 or TIM-1. which mediate immunoregulatory pathways.
PSG1 is implicated in modulating immune responses, including promoting anti-inflammatory cytokine production (e.g., IL-10) and suppressing T-cell activation, mechanisms vital for preventing maternal immune rejection of the fetus. Dysregulation of PSG1 has been associated with pregnancy complications (e.g., preeclampsia) and certain cancers, where its expression may influence tumor progression or immune evasion.
Recombinant PSG1 serves as a valuable tool in biomedical research, aiding in elucidating maternal-fetal tolerance mechanisms, developing diagnostic biomarkers for pregnancy disorders, and exploring therapeutic strategies for immune-related conditions or cancer. Its study also contributes to understanding the broader roles of immunoglobulin-like proteins in human physiology and pathology.
×
